Active Awards Portfolio Dashboard

It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and clinical stage research. Check out our portfolio of active research awards in our interactive dashboard below. For a detailed list of CIRM-funded clinical trials, visit our Clinical Trials Dashboard.

Filter Awards

Disease

Therapeutic or Technology

Disease	Cell Type	Therapeutic or Technology	Institution	Project Objective
IPEX Syndrome, Immune Disease	Vital Research Opportunity	Gene Therapy, cell free	Stanford	IND
Parkinson's Disease	Vital Research Opportunity	Gene Therapy, cell free	Brain Neurotherapy Bio	Clinical Trial, Phase 1 or Phase 1/2
Type 1 diabetes	Embryonic Stem Cell	Gene-modified, donor cell therapy	Lundquist Institute	Development Candidate, Proof of Concept
Liver Disease	iPS Cell	Gene-modified, donor cell therapy	CHLA	Development Candidate, Proof of Concept
COVID-19, Respiratory Disorders	iPS Cell	Gene-modified, donor cell therapy	USC	Development Candidate, Proof of Concept
Blood Cancer	Adult Stem Cell	Gene-modified, donor cell therapy	Angiocrine	Clinical Trial, Phase 1 or Phase 1/2
COVID-19	Adult Stem Cell	Gene-modified, donor cell therapy	UCLA	Development Candidate, Proof of Concept
COVID-19	Embryonic Stem Cell, iPS Cell	Gene-modified, donor cell therapy	COH	Proof of Concept
Parkinson's Disease	Adult Stem Cell	Gene-modified, donor cell therapy	UCSF	IND
Amyotrophic Lateral Sclerosis	Adult Stem Cell	Gene-modified, donor cell therapy	Cedars-Sinai	Clinical Trial, Phase 1 or Phase 1/2
Cancer	Adult Stem Cell	Gene-modified, donor cell therapy	UCLA	Development Candidate, Proof of Concept
Ovarian Cancer	Adult Stem Cell	Gene-modified, donor cell therapy	COH	Pre-IND/IDE or Equivalent
COVID-19	Adult Stem Cell	Gene-modified, donor cell therapy	COH	Development Candidate, Proof of Concept
Ovarian Cancer	iPS Cell	Gene-modified, donor cell therapy	UCSD	Development Candidate, Proof of Concept
Sickle Cell Disease	Adult Stem Cell	Gene-modified, personalized cell therapy	UCLA	Clinical Trial, Phase 1 or Phase 1/2
B cell cancers, Leukemia	Adult Stem Cell	Gene-modified, personalized cell therapy	Stanford	Clinical Trial, Phase 1 or Phase 1/2
Cancer	Cancer Stem Cell	Gene-modified, personalized cell therapy	UCSD	Pre-IND/IDE or Equivalent
Beta Thalassemia	Adult Stem Cell	Gene-modified, personalized cell therapy	Sangamo	Clinical Trial, Phase 1 or Phase 1/2
Sickle Cell Disease	Adult Stem Cell	Gene-modified, personalized cell therapy	UCSF	Pre-IND/IDE or Equivalent
Immune Disease, Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID)	Adult Stem Cell	Gene-modified, personalized cell therapy	Orchard Therapeutics	Clinical Trial, Phase 2
Cystinosis, Kidney Failure	Adult Stem Cell	Gene-modified, personalized cell therapy	UCSD	Clinical Trial, Phase 1 or Phase 1/2
HIV/AIDS	Adult Stem Cell	Gene-modified, personalized cell therapy	COH	Clinical Trial, Phase 1 or Phase 1/2
Lung Cancer	Adult Stem Cell	Gene-modified, personalized cell therapy	UCLA	Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer, Breast Cancer	Adult Stem Cell	Gene-modified, personalized cell therapy	COH	Clinical Trial, Phase 1 or Phase 1/2
HIV-related Lymphoma, HIV/AIDS	Adult Stem Cell	Gene-modified, personalized cell therapy	UC Davis	Clinical Trial, Phase 1 or Phase 1/2
Immune Disease, X-linked Chronic Granulomatous Disease	Adult Stem Cell	Gene-modified, personalized cell therapy	UCLA	Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer	Adult Stem Cell	Gene-modified, personalized cell therapy	COH	Clinical Trial, Phase 1 or Phase 1/2
Leukemia, Acute Myeloid (AML)	Cancer Stem Cell	Gene-modified, personalized cell therapy	UCSF	Pre-IND/IDE or Equivalent
Canavan Disease	iPS Cell	Gene-modified, personalized cell therapy	COH	Pre-IND/IDE or Equivalent
Leukemia, Acute Myeloid (AML), Multiple Myeloma	Adult Stem Cell	Gene-modified, personalized cell therapy	UCLA	Pre-IND/IDE or Equivalent
Multiple Myeloma	Adult Stem Cell	Gene-modified, personalized cell therapy	Poseida Therapeutics	Clinical Trial, Phase 1 or Phase 1/2
Sickle Cell Disease	Adult Stem Cell	Gene-modified, personalized cell therapy	Boston Children's Hospital	Clinical Trial, Phase 2
Brain Cancer	Adult Stem Cell	Gene-modified, personalized cell therapy	COH	IND
Epidermolysis Bullosa	iPS Cell	Gene-modified, personalized cell therapy	Stanford	Pre-IND/IDE or Equivalent
Brain Cancer	Adult Stem Cell	Gene-modified, personalized cell therapy	UCSF	Development Candidate, Proof of Concept
Ovarian Cancer	Adult Stem Cell	Gene-modified, personalized cell therapy	COH	Development Candidate, Proof of Concept
Blood Disorders, Immune Disease	Adult Stem Cell	Gene-modified, personalized cell therapy	UCLA	Proof of Concept
HIV/AIDS, Immune Disease	Adult Stem Cell	Gene-modified, personalized cell therapy	UCSF	Clinical Trial, Phase 1 or Phase 1/2
Bone or Cartilage Disease	Adult Stem Cell	Gene-modified, personalized cell therapy	Rocket Pharmaceuticals, Inc.	Clinical Trial, Phase 1 or Phase 1/2
Heart Disease, Danon Disease	Adult Stem Cell	Gene-modified, personalized cell therapy	UCSD	Development Candidate, Proof of Concept
Hyper IgM Syndrome, Immune Disease	Adult Stem Cell	Gene-modified, personalized cell therapy	UCLA	Pre-IND/IDE or Equivalent
Sickle Cell Disease	Adult Stem Cell	Gene-modified, personalized cell therapy	UCSF	IND
Immune Disease, Severe Combined Immunodeficiency, X-linked (X-SCID)	Adult Stem Cell	Gene-modified, personalized cell therapy	St. Jude	Clinical Trial, Phase 1 or Phase 1/2
Sarcoma	Adult Stem Cell	Gene-modified, personalized cell therapy	UCLA	Clinical Trial, Phase 1 or Phase 1/2
Blood Disorders	Adult Stem Cell	Gene-modified, personalized cell therapy	UCLA	Development Candidate, Proof of Concept
Severe Combined Immunodeficiency, Artemis deficient (ART-SCID)	Adult Stem Cell	Gene-modified, personalized cell therapy	UCSF	Clinical Trial, Phase 1 or Phase 1/2
Immune Disease, Leukocyte Adhesion Deficiency	Adult Stem Cell	Gene-modified, personalized cell therapy	Rocket Pharmaceuticals, Inc.	Clinical Trial, Phase 1 or Phase 1/2
Hearing Loss	iPS Cell	Model system development	USC	Proof of Concept, Tool/Resources/Bottleneck
COVID-19, Respiratory Disorders	Adult Stem Cell	Model system development	UCLA	Development Candidate, Proof of Concept, Tool/Resources/Bottleneck
COVID-19	iPS Cell	Model system development	UC Berkeley	Proof of Concept

California's Stem Cell Agency

California Institute for Regenerative Medicine

Active Awards Portfolio Dashboard

Filter Awards

Pages

aa Multiple Diseases (Centers & Resoures)
Aging
Arthritis
Blood Disorders
– Alpha Thalassemia Major
– Anemia
– Beta Thalassemia
– Bone Marrow Transplant and Viral Infection
– Hemophilia A
– Hyper IgM Syndrome
– IPEX Syndrome
– Leukocyte Adhesion Deficiency
– Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID)
– Severe Combined Immunodeficiency, Artemis deficient (ART-SCID)
– Severe Combined Immunodeficiency, X-linked (X-SCID)
– Sickle Cell Disease
– X-linked Chronic Granulomatous Disease
Bone or Cartilage Disease
– Intervertebral disc degeneration
– Osteoarthritis
– Osteonecrosis
– Osteoporosis, malignant infantile
Cancer
– Blood Cancer
–– Acute Myeloid Leukemia
–– B cell cancers
–– HIV-related Lymphoma
–– Leukemia
–– Leukemia, Acute Myeloid (AML)
–– Multiple Myeloma
– Solid Tumors
–– Brain Cancer
–– Breast Cancer
–– Colon Cancer
–– Lung Cancer
–– Melanoma
–– Ovarian Cancer
–– Pancreatic Cancer
–– Prostate Cancer
–– Sarcoma
–– Skin cancer
Developmental Disorders
Fertility
Genetic Disorder
Hearing Loss
Heart Disease
– Heart disease associated with Duchenne muscular dystrophy
– Heart failure
– Pulmonary Hypertension
Immune Disease
– Thymic Disorder, 22q11 Deletion/DiGeorge
Incontinence
Infectious Disease
– COVID-19
– HIV/AIDS
– Zika virus
Kidney Disease
– Kidney Failure
Metabolic Disorders
– Cystinosis
– Danon Disease
– Diabetes
–– Diabetic Wounds
–– Type 1 diabetes
– Intestinal Disease
–– Inflammatory bowel disease
– Liver Disease
Multiple Indications (Alpha Clinics)
Neurological Disorders
– Alzheimer's Disease
– Amyotrophic Lateral Sclerosis
– Autism
– Brain Injury, hypoxic, ischemic
– Canavan Disease
– Dementia
– Epilepsy
– Huntington's Disease
– Multiple Sclerosis
– Neuropathy
– Parkinson's Disease
– Rett's Syndrome
– Spina Bifida
– Spinal Cord Injury
– Spinal Muscular Atrophy
– Stroke
– Traumatic Brain Injury
Other
Pediatrics
Respiratory Disorders
– Cystic Fibrosis
– Lung Disease, Fibrosis
Skeletal/Smooth Muscle disorders
– Bladder or Urinary Tract Disorder
– Muscular Dystrophy
Skin Disease
– Epidermolysis Bullosa
Toxicity
Trauma
Vascular Disease
Vision Loss
– Age-related macular degeneration
– Corneal Damage
– Retinitis Pigmentosa

Therapeutic Approach
– Biologic
–– Antibody
–– Convalescent Plasma
–– Exosomes based therapy
–– Gene modification
–– Nucleic acid based therapy
–– Protein/peptide therapy
–– Vaccine
– Gene Therapy (All)
–– Gene Therapy, cell free
–– Gene-modified, donor cell therapy
–– Gene-modified, personalized cell therapy
– Small molecule therapy
– Device
– Donor cell therapy
– Personalized cell therapy
– Other Components
Technology
– Assay development
– Cell Line Generation-Resource
– Diagnostic Test
– Gene editing tools
– Cell delivery or targeting
– Cell imaging & tracking
– Cell processing & handling
– Exploring disease mechanisms
– Exploring stem cell mechanisms
– Immune tolerance/management
– Model system development
– Specific Cell Type Derivation
– Therapeutic target discovery
– Tissue engineering